A Revolution in R&D

More documents

Recommendations

Info

4 About the Authors About the Authors Peter Tollman is a vice president in the Boston office and leads BCG's biopharmaceutical R&D business. Philippe Guy is a senior vice president in the Paris office and leads the worldwide Health Care practice. Jill Altshuler is a manager in the Boston office and a key contributor to BCG’s genomics initiative. Alastair Flanagan is a vice president in the London office and leads the U.K. Health Care practice. Michael Steiner is a senior vice president in the Munich office and leads the German Health Care practice. Acknowledgments Sarah Cairns-Smith (Boston) pioneered BCG’s investigation of genomics. Samantha Gray (Boston) has made significant contributions throughout the research and writing phases of the report. The authors would like to thank the advisory team: Oliver Fetzer (Boston), Hamilton Moses (Washington, D.C.), Niko Vrettos (Düsseldorf), and Craig Wheeler (Boston). The authors would also like to acknowledge the contributions of the project team: Dierk Beyer (Frankfurt), Markus Hildinger (Boston), Raphael Lehrer (Washington D.C.), Nancy Macmillan (Boston), Jonathan Montagu (London), and Joanne Smith-Farrell (Washington, D.C.). For Further Contact The authors welcome your questions and comments. For inquiries about this report or BCG’s Health Care practice, please contact: Alastair Flanagan, London e-mail: flanagan.alastair@bcg.com Philippe Guy, Paris e-mail: guy.philippe@bcg.com Mark Lubkeman, Los Angeles e-mail: lubkeman.mark@bcg.com Michael Steiner, Munich e-mail: steiner.michael@bcg.com Martin Reeves, Tokyo e-mail: reeves.martin@bcg.com Peter Tollman, Boston e-mail: tollman.peter@bcg.com
Foreword To meet growth targets, pharmaceutical companies are going to have to increase R&D productivity. By a fortunate coincidence, that crisis in expectation is being counterbalanced by a surge of opportunity. Recent years have seen astonishing advances in technology and explosions of data, which are driving two waves of change through the industry—a genomics wave and a genetics wave—and radically reshaping R&D methods and economics in the process. Biopharmaceutical R&D is moving into a new era: almost every link in the value chain has the potential for tremendous boosts in efficiency or success. But these advances are not assured. Technological hurdles have yet to be overcome, particularly in the genetics wave. Moreover, because the productivity boosts are likely to be unequal and uncoordinated, the value chain itself will demand reconfiguring. And so too, in consequence, will many traditional operational procedures and organizational structures. The repercussions of genomics, in other words, are going to reach the furthest recesses of corporate constitution and culture. A true revolution, in short—and one that is already well under way. BCG has evaluated deeply the economic and business implications of these disruptions. To bolster our internal understanding, we gathered information and perspectives in an extensive program of interviews with leading R&D scientists and executives. Our findings—based on the combination of these interviews, economic modeling, and client casework—form the substance of this report. Its three sections are devoted respectively to the impact of genomics, the impact of genetics, and some of the strategic and operational implications for biopharmaceutical firms. The first two sections have already been published separately. They generated considerable publicity, and— more important—considerable comment. We now look forward to your further responses to the report as a whole. Philippe Guy Senior Vice President 5
Page 1 and 2: A Revolution in R&D HOW GENOMICS AN
Page 3 and 4: A Revolution in R&D HOW GENOMICS AN
Page 5: Table of Contents ABOUT THE AUTHORS
Page 9 and 10: cogenetics). The productivity gains
Page 11: Introduction Throughout the pharmac
Page 14 and 15: 12 The Opportunities What is the im
Page 16 and 17: 14 and generally helping to optimiz
Page 18 and 19: 16 Cellomics are well positioned to
Page 20 and 21: 18 trials, if the company were able
Page 22 and 23: 20 almost to that of more familiar
Page 24 and 25: 22 UPSTART START-UPS—THE COMPETIT
Page 26 and 27: 24 Chapter 2: The Impact of Genetic
Page 28 and 29: 26 genetics-based form of pharmacog
Page 30 and 31: 28 DISEASE GENETICS—VARIOUS APPRO
Page 32 and 33: 30 Efficiency improvements in targe
Page 34 and 35: 32 duce targets high in quality but
Page 36 and 37: 34 would be excluded from the trial
Page 38 and 39: 36 Given these technological limita
Page 40 and 41: 38 Side-effect-based pharmacogeneti
Page 42 and 43: 40 moves, along with the relative s
Page 44 and 45: 42 POTENTIAL SAVINGS—FROM THEORET
Page 46 and 47: 44 ogy—to discover new drugs. Bro
Page 48 and 49: 46 INDUSTRY CHANGES The genomics la
Page 50 and 51: 48 Selecting Technologies According
Page 52 and 53: 50 tions, interfaces, and so on. Th
Page 54 and 55: 52 CASE STUDY: REDISCOVERING DISCOV
Page 56 and 57:
54 other—often literally—on col
Page 58 and 59:
56 The formidable operational and o
Page 61 and 62:
Methodology The many diverse studie
Page 63 and 64:
The Boston Consulting Group publish
show all

A Revolution in R&D

Create successful ePaper yourself

Delete template?

Save as template?